Jordan Milner, MD - Research

Research at a glance

Focus

Dr. Milner's research focus is graft manipulation. The utilization of graft manipulation permits decreased morbidities and improved quality of life in stem cell transplant recipients.

Active clinical trials

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and鈥�

Investigator: Jordan Milner
Status: Accepting Candidates
Ages: N/A - 39 Years
Sexes: All

Alpha/beta T cell and CD19+ B cell depletion in Allogeneic Stem Cell Transplantation

This study will assess the safety, efficacy, and feasibility of 鈲�/尾 CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile鈥�

Investigator: Jordan Milner
Status: Accepting Candidates
Ages: 6 Months - 39 Years
Sexes: All

NYMC-571

This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell鈥�

Investigator: Jordan Milner
Status: Accepting Candidates
Ages: 6 Months - 34 Years
Sexes: All

My publications

9 publications

2024

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.

Leukemia research reports

鈥�

2024

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial

Frontiers in Neurology

鈥�

2024

The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.

Pediatric transplantation

鈥�

2023

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Blood

鈥�

2022

Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients

Cureus

BOB体育

Research at a glance

Focus

Active clinical trials

My publications

Filter publications

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial

The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients